ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Molecular Network of Neutrophil Extracellular Traps in Hepatocellular Carcinoma: Biogenesis, Function, and Therapeutic Implications.Molecules (Basel, Switzerland) · 2026Review
- In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Neutrophil extracellular traps (NETs) released by activated neutrophils in the tumor microenvironment has emerged as a pivotal mediator in promoting tumor metastasis. The alteration of the subcellular localization of neutrophil elastase (NE) is crucial for NETs formation. The majority of NE (≈80%) translocate from azurophilic granules to the nucleus, facilitating histone degradation and chromatin decondensation. A few NE are transported to the cell membrane, a unique feature of activated neutrophils that distinguishes them from other leukocyte subpopulations. To address NETs-mediated HCC metastasis, a peptidic nanomaterial (FTP-NPs) is developed that specifically binds NE on activated neutrophil membranes and undergoes in situ fibrillar transformation, forming NE-fibril clusters. These NE-fibril clusters deactivate NE by altering their conformation or binding mode. Subsequently, a series of feedback mechanisms is triggered, which regulates NE membrane concentration by promoting its transport to the membrane rather than the nucleus. The NE-fibril clusters can remain on the activated neutrophil membrane for an extended period, enabling continuous binding and deactivation of newly transported NE, thereby reversing the formation of NETs. Besides, the extracellular NE-fibril clusters also act as a physical barrier to prevent NETs from adhering to tumor cells, further disrupting the metastatic cascade. In vitro, in vivo, and single-cell RNA sequencing (scRNA-seq) data confirm that FTP-NPs significantly reduce NETs formation, reduce metastatic burden, and enhance antitumor immune response. Compared with commercial NE inhibitors, this strategy precisely and locally regulates NE subcellular distribution within neutrophils in tumor tissue, minimizing off-target effects and systemic toxicity. The NE-fibril clusters may establish an innovative therapeutic approach for NETs-mediated tumor metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.